Covariability of seasonal temperature and precipitation over the Iberian Peninsula in high-resolution regional climate simulations (1001–2099)

Precipitation and surface temperature are interdependent variables, both as a response to atmospheric dynamics and due to intrinsic thermodynamic relationships and feedbacks between them. This study analyzes the covariability of seasonal temperature (T) and precipitation (P) across the Iberian Peninsula (IP) using regional climate paleosimulations for the period 1001–1990, driven by reconstructions of external forcings. Future climate (1990–2099) was simulated according to SRES scenarios A2 and B2. These simulations enable exploring, at high spatial resolution, robust and physically consistent relationships.This study was supported by the Spanish government and the Fondo Europeo de Desarrollo Regional (FEDER) through the project SPEQ-TRES (CGL2011-29672-C02-02). J.P. Montávez also acknowledges the financial support from Fundacion Seneca (Ref 19640/EE/14)

Depresión de aparición tardía y su relación con la demencia vascular en el anciano

Introducción: la demencia vascular es un síndrome de naturaleza crónica y progresiva, caracterizado por una perturbación de diversas funciones mentales superiores, la cual conlleva a un deterioro global en las esferas comportamental, social, emocional y biológica del individuo. Objetivo: describir los aspectos más actualizados y relevantes en demencia, específicamente la demencia vascular, su asociación con depresión de aparición tardía, mecanismos fisiopatológicos, el impacto en la funcionalidad del anciano y los puntos más destacados en el tamizaje y diagnóstico de ambas entidades. Metodología: se realizó una revisión sistemática de la literatura sobre demencia vascular y su asociación con la depresión de aparición tardía en las bases de datos PubMed, ScienceDirect y Ovid durante los meses de mayo a agosto de 2013. Resultados: se encontraron 62 artículos con información actualizada. Destaca la clara asociación entre ambas patologías, con una prevalencia global de trastornos depresivos de 27,41%, de los cuales 44,41% corresponden a sujetos con demencia de tipo vascular, 32,48% a otros tipos de demencia no especificada y 18,53% a Enfermedad de Alzheimer. Conclusión: la demencia vascular es una entidad que ha incrementado la morbilidad de la población geriátrica, por lo cual se hace cada vez más necesaria la aplicación sistemática de métodos de tamizaje reproducibles, económicos y confiables, con el objetivo de favorecer el diagnóstico y la detección precoz. En nuestro concepto dichos métodos de tamizaje deberían incluir dentro de sus criterios diagnósticos a los trastornos depresivos, dada la relación de su aparición en etapas tardías de la vida con el posterior desarrollo de deterioro cognitivo y demencia de tipo vascular.Background: Vascular dementia is a syndrome of chronic progressive nature, characterized by a disturbance of various higher mental functions, which leads to an overall deterioration in the behavioral, social, emotional and biological areas of the individual. Objective: explain and describe the most current and relevant issues in dementia, vascular type specifically, and its association with late-onset depression, pathophysiological mechanisms, the impact they represent on the functionality of the elderly patient and the most prominent points in the screening and diagnosis of both entities. Methods: A systematic review of the literature on vascular dementia and its association with late-onset depression in PubMed and ScienceDirect data was performed. Results: 64 updated articles with information about the subject to develop were found. Highlights the clear association between the two conditions described, with an overall prevalence of depressive disorders of 27.41%, of which 44.41% were subjects with vascular dementia, 32.48% correspond to other types of non-specified dementia and 18.53% to Alzheimer’s disease. Conclusion: Vascular dementia is an entity that has increased morbidity in the geriatric population, because of this, the systematic application of reproducible, economical and reliable screening methods becomes more necessary, with the aim of favoring early diagnosis and detection, in our opinion such screening methods should include depressive disorders as part of their diagnostic criteria, due to the relationship between its aparittion in the later stages of life and the subsequent development of cognitive impairment and vascular dementia. &nbsp

Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial

Vitamin D plays a major role in bone health and probably also in multiple extraskeletal acute and chronic diseases. Although supplementation with calcifediol, a vitamin D metabolite, has demonstrated efficacy and safety in short-term clinical trials, its effects after long-term monthly administration have been studied less extensively. This report describes the results of a 1-year, phase III-IV, double-blind, randomized, controlled, parallel, multicenter superiority clinical trial to assess the efficacy and safety of monthly calcifediol 0.266 mg versus cholecalciferol 25,000 IU (0.625 mg) in postmenopausal women with vitamin D deficiency (25(OH)D < 20 ng/mL). A total of 303 women were randomized and 298 evaluated. Patients were randomized 1:1:1 to calcifediol 0.266 mg/month for 12 months (Group A1), calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months (Group A2), and cholecalciferol 25,000 IU/month (0.625 mg/month) for 12 months (Group B). By month 4, stable 25(OH)D levels were documented with both calcifediol and cholecalciferol (intention-to-treat population): 26.8 ± 8.5 ng/mL (Group A1) and 23.1 ± 5.4 ng/mL (Group B). By month 12, 25(OH)D levels were 23.9 ± 8.0 ng/mL (Group A1) and 22.4 ± 5.5 ng/mL (Group B). When calcifediol treatment was withdrawn in Group A2, 25(OH)D levels decreased to baseline levels (28.5 ± 8.7 ng/mL at month 4 versus 14.4 ± 6.0 ng/mL at month 12). No relevant treatment-related safety issues were reported in any of the groups. The results confirm that long-term treatment with monthly calcifediol in vitamin D-deficient patients is effective and safe. The withdrawal of treatment leads to a pronounced decrease of 25(OH)D levels. Calcifediol presented a faster onset of action compared to monthly cholecalciferol. Long-term treatment produces stable and sustained 25(OH)D concentrations with no associated safety concerns.This study was funded by Faes Farma, S.A. and Bruno Farmaceutici S.p.A. The authors wish to thank the study participants, research staff, the secondary investigators of the Osteoferol study group, the home nursing staff (Emibet), and Faes Farma clinical research team: Paula Arranz Gutiérrez, Lorena Elgezabal González, Mariana Frau Usoz, and Iñigo Saez Riesco. Medical writing support was provided by Francisco López de Saro (Trialance SCCL), funded by Faes Farma, S.A

Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial

Vitamin D has shown to play a role in multiple diseases due to its skeletal and extraskeletal actions. Furthermore, vitamin D deficiency has become a worldwide health issue. Few supplementation guidelines mention calcifediol treatment, despite being the direct precursor of calcitriol and the biomarker of vitamin D status. This 1-year, phase III-IV, double-blind, randomized, controlled, multicenter clinical trial assessed the efficacy and safety of calcifediol 0.266 mg soft capsules in vitamin D-deficient postmenopausal women, compared to cholecalciferol. Results reported here are from a prespecified interim analysis, for the evaluation of the study's primary endpoint: the percentage of patients with serum 25-hydroxyvitamin D (25(OH)D) levels above 30 ng/ml after 4 months. A total of 303 patients were enrolled, of whom 298 were included in the intention-to-treat (ITT) population. Patients with baseline levels of serum 25(OH)D <20 ng/ml were randomized 1:1:1 to calcifediol 0.266 mg/month for 12 months, calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months, and cholecalciferol 25,000 IU/month for 12 months. At month 4, 35.0% of postmenopausal women treated with calcifediol and 8.2% of those treated with cholecalciferol reached serum 25(OH)D levels above 30 ng/ml (p < 0.0001). The most remarkable difference between both drugs in terms of mean change in serum 25(OH)D levels was observed after the first month of treatment (mean ± standard deviation change = 9.7 ± 6.7 and 5.1 ± 3.5 ng/ml in patients treated with calcifediol and cholecalciferol, respectively). No relevant treatment-related safety issues were reported in any of the groups studied. These results thus confirm that calcifediol is effective, faster, and more potent than cholecalciferol in raising serum 25(OH)D levels and is a valuable option for the treatment of vitamin D deficiency

Accesibilidad en los espacios públicos urbanizados

El libro, coordinado por el Director de ACCEPLAN, Fernando Alonso López, viene a ser un reflejo de los avances entorno a la búsqueda de accessibilidad universal en los espacios públicos urbanizados. Para aproximarse a la realidad normativa y técnica de la Orden Ministerial el libro se estructura en artículos referentes al contexto normativo, a los contenidos de la Orden, y a reflexiones y criterios en torno a la accesibilidad en la ciudad. Del conjunto de artículos, por su variedad y por su carácter multidiciplinar, se extrae un libro de referencia que ofrece la variedad de enfoques del tema y que ayuda a interpretar mejor la Orden Ministerial, su contribución a los objetivos de la Ley 51/2003 de Igualdad de Oportunidades No Discriminación y Accesibilidad Universal, LIONDAU, y su utilidad en la comformación de unas ciudades cada vez más abiertas a la diversidad funcional y a la convivencia.El llibre, coordinat pel director de ACCEPLAN, Fernando Alonso López, ve a ser un reflex dels avenços entorn de la recerca d'accessibilitat universal en els espais públics urbanitzats. Per conèixer un realitat normativa i tècnica de l'Ordre Ministerial el llibre s'estructura en articles referents al context normatiu, als continguts de l'Ordre, ja reflexions i criteris al voltant de l'accessibilitat a la ciutat. Del conjunt d'articles, per la seva varietat i pel seu caràcter multidiciplinar, s'extreu un llibre de referència que ofereix la varietat d'enfocaments del tema i que ajuda a interpretar millor l'Ordre Ministerial, la seva contribució als objectius de la Llei 51/2003 de Igualtat d'Oportunitats No Discriminació i Accessibilitat Universal, LIONDAU, i la seva utilitat en la comformación d'unes ciutats cada vegada més obertes a la diversitat funcional ia la convivència

Reseñas de libros

[EN] García Bueno, Antonio. Dibujando la Alhambra y su Entorno (por Antonio J. Gómez-Blanco Pontes) pp. 4.-- Pozo, José M.; García-Diego, Hector y García, Izaskun ( por Carlos Montes Serrano) pp. 5.-- Laura Carlevaris, Mónica Filippa (coordinadoras)(por Antonio Álvaro Tordesillas) pp. 5 y 6.-- Esteve Secall, Carlos E. La ciencia gnomónica en la España del siglo de Oro (por Joaquín Casado de Amezúa Vázquez ) pp. 6 y 7.-- Franco Taboada, José Antonio. Geometría descriptiva para la representación arquitectónica (por Lluís Villanueva Bartrina) pp. 7 y 8.--Raposo Grau, Javier Fco; Butragueño Díaz-Guerra y Paredes Maldonado, Miguel. La ciudad como espacio de relaciones dinámicas (por Margarita de Luxán García de Diego) pp. 8 y 9.-- Castellanos Gómez, Raúl. Plan Poché (por Daniel García-Escudero) pp. 9 y 10.-- Gutiérrez Mozo, María Alia; Castilla Pascual, Francisco Javier y Real Tomás, María del Carmen. 70 años de arquitectura en Albacete: 1936-2006 ( por Javier Poyatos Sebastián) pp. 10 y 11.-- García Sánchez, María Teresa. De la ciudad en vibración al ser resonante: una investigación a propósito de los conciertos de campanas de Llorenç Barber ( por Fernando Ochoa Gómez) pp. 11.-- Pernas Alonso, Inés. Escaleras de piedra en los conjuntos monásticos de la provincia de Ourense entre los siglos xVI y xVIII. Análisis gráfico (por José Antonio Franco Taboada) pp. 12 y 13.-- Rodríguez Moreno, Dª Concepción. El palacio de Pedro I en los Reales Alcázares de Sevilla: estudio y análisis (por Joaquín Casado de Amezúa) pp. 13 y 14.—Jeremías, Pablo y Gutierrez, Juan. Tiempo de arquitectura ( por Carlos L. Marcos) pp. 14 y 15.-- Domingo Gresa, Jorge. El dibujo de arquitectura en la formación de la ciudad de Alicante: Fondo Documental del Archivo Municipal (1691-1860)(por Gaspar Jaén i Urbàn)pp.15.-- García-Solera, Javier. Dibujos y palabras en la habitación tranquila (por Gaspar Jaen) pp. 16 y 17.—Anne Griswold Tyng (1920-2011)( por Noelia Galván Desvaux)pp. 18 y 19 .-- Oscar Niemeyer Un adiós al último maestro del siglo XX(por Noelia Galván Desvaux)pp. 20 y 21Gómez-Blanco Pontes, AJ.; Montes Serrano, C.; Tordesillas, AÁ.; Casado De Amezúa Vázquez, J.; Villanueva Bartrina, L.; De Luxán García De Diego, M.; García-Escudero, D.... (2013). Reseñas de libros. EGA. Revista de Expresión Gráfica Arquitectónica. 18(21):4-21. https://doi.org/10.4995/ega.2013.1708SWORD421182

Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density.

OBJECTIVES: To identify genetic determinants of susceptibility to clinical vertebral fractures, which is an important complication of osteoporosis. METHODS: Here we conduct a genome-wide association study in 1553 postmenopausal women with clinical vertebral fractures and 4340 controls, with a two-stage replication involving 1028 cases and 3762 controls. Potentially causal variants were identified using expression quantitative trait loci (eQTL) data from transiliac bone biopsies and bioinformatic studies. RESULTS: A locus tagged by rs10190845 was identified on chromosome 2q13, which was significantly associated with clinical vertebral fracture (P=1.04×10-9) with a large effect size (OR 1.74, 95% CI 1.06 to 2.6). Bioinformatic analysis of this locus identified several potentially functional SNPs that are associated with expression of the positional candidate genes TTL (tubulin tyrosine ligase) and SLC20A1 (solute carrier family 20 member 1). Three other suggestive loci were identified on chromosomes 1p31, 11q12 and 15q11. All these loci were novel and had not previously been associated with bone mineral density or clinical fractures. CONCLUSION: We have identified a novel genetic variant that is associated with clinical vertebral fractures by mechanisms that are independent of BMD. Further studies are now in progress to validate this association and evaluate the underlying mechanism

Herramientas de aprendizaje para estudiantes de secundaria: Aplicación de la Genética y la Genómica

Depto. de Genética, Fisiología y MicrobiologíaFac. de Ciencias BiológicasFALSEsubmitte

Relatoría III jornadas en tecnologías de la información, telecomunicaciones y el ecosistema digital - Relatoría conferencias magistrales

47 página

Conversatorio: “25 años de las Comisiones de Regulación. Su importancia para Colombia, para la creación de mercados de servicios públicos y telecomunicaciones"

27 página